RIDE THERAPEUTICS THE MOLECULAR LOGISTICS COMPANY
Live / Applied — First extension granted (statement of use) (as of 20 Oct 2025)
What this means for you
Not registered yet, but its 10 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98351758
- Mark type
- Stylized text
- Filed
- 10 Jan 2024
- Published for opposition
- 18 Mar 2025
- Attorney of record
- Devon E. White
Goods and services
- Class 042 — Scientific and technological services: Medical and scientific research services; Research and development of drug delivery platforms; Research and development in the field of technology and micro- and nano-engineering, namely, development of drug delivery agents for use in pharmaceutical and biomedical industry; Development of new technology for others for enabling the engineering and modification of mRNA and genes for the purpose of developing molecular and cellular drug delivery agents for use in pharmaceutical and biomedical industry
Owner
- Ride Therapeutics, Inc., Cambridge, MA, US
- Ride Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 23 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Oct 2025 — SOU EXTENSION 1 GRANTED
- 20 Oct 2025 — SOU EXTENSION 1 FILED
- 20 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 13 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Mar 2025 — PUBLISHED FOR OPPOSITION
- 12 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 06 Nov 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 06 Nov 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 19 Aug 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED